![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Durect Completes Dosing of Sufentanil Patch Study, Pain Relief Depot Study
Durect Completes Dosing of Sufentanil Patch Study, Pain Relief Depot Study
Durect, an emerging specialty pharmaceuticals systems company, has announced the completion of dosing of the Phase I pharmacokinetic study for Durect's Transdur-based sufentanil patch.
The company also announced the completion of dosing of the first cohort of the ongoing Phase II clinical study for Durect's Saber-based postoperative pain relief depot product and is actively enrolling patients in the second cohort.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct